Ophthalmic technology specialist Glaukos Corp. has completed patient enrollment in the pivotal phase of its investigational device exemption trial for the Istent Supra Suprachoroidal Micro-Bypass Stent. The San Clemente, Calif.-based company's clinical trial includes 36 sites and 505 subjects with mild-to-moderate primary open-angle glaucoma and cataracts. Read More
